Summary

In the largest trial to date of patients with medically managed acute coronary syndrome without revascularization, prasugrel did not improve outcomes, compared with clopidogrel during 2.5 years of follow-up among patients <75 years. The findings are from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes [TRILOGY ACS] study [Roe MT et al. N Engl J Med 2012].